Mastering Neurological & Psychiatric Conditions in Geriatrics for the BCGP Board Certified Geriatric Pharmacist Exam

Introduction: Navigating Neurological & Psychiatric Conditions in Geriatrics for the BCGP Exam

As of April 2026, the landscape of geriatric pharmacy continues to evolve, with a particular emphasis on the nuanced management of neurological and psychiatric conditions in older adults. For candidates preparing for the BCGP Board Certified Geriatric Pharmacist practice questions, mastering this domain is not merely academic; it is fundamental to providing optimal patient care. This topic encompasses a wide array of disorders, from neurodegenerative diseases like Alzheimer's and Parkinson's to common psychiatric illnesses such as depression, anxiety, and the acute confusion state of delirium.

The complexity arises from several factors unique to the geriatric population: atypical disease presentations, altered pharmacokinetics and pharmacodynamics, the ubiquitous challenge of polypharmacy, and a heightened susceptibility to adverse drug reactions. A geriatric pharmacist's expertise is crucial in navigating these challenges, ensuring safe, effective, and patient-centered medication management. This mini-article will delve into the core concepts, illustrate how these topics typically appear on the BCGP exam, offer effective study strategies, and highlight common pitfalls to avoid.

Key Concepts: A Deep Dive into Geriatric Neuropsychopharmacology

Understanding the key neurological and psychiatric conditions affecting older adults, along with their pharmacological management, is paramount. Here's a breakdown of essential concepts:

Dementia Syndromes (Alzheimer's Disease, Vascular Dementia, Lewy Body Dementia)

• Pathophysiology: Understand the distinct pathological hallmarks (e.g., amyloid plaques and neurofibrillary tangles in Alzheimer's, cerebrovascular damage in vascular dementia, alpha-synuclein deposits in Lewy Body).
• Diagnosis: Clinical criteria, often involving cognitive assessments (MMSE, MoCA) and neuroimaging.
• Pharmacological Management:
  • Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine): Mechanism (increase acetylcholine), indications (mild to moderate Alzheimer's, some benefit in severe, Lewy Body, Parkinson's-related dementia), common adverse effects (GI upset, bradycardia, insomnia).
  • NMDA Receptor Antagonist (Memantine): Mechanism (blocks glutamate toxicity), indications (moderate to severe Alzheimer's), common adverse effects (dizziness, headache, confusion).
  • Newer Agents (e.g., Lecanemab, Donanemab): Monoclonal antibodies targeting amyloid-beta. Understand their indications (early Alzheimer's), administration (IV infusion), and significant adverse effects (ARIA-E, ARIA-H). Recognize these are evolving treatments as of April 2026.
• Non-pharmacological Strategies: Behavioral interventions, environmental modifications, caregiver support.

Delirium

• Definition: Acute onset, fluctuating disturbance of attention and cognition. Differentiate from dementia and depression.
• Risk Factors & Causes: Infections, dehydration, polypharmacy (especially anticholinergics, benzodiazepines, opioids), surgery, pain, electrolyte imbalances.
• Management: Primary focus on identifying and treating the underlying cause. Non-pharmacological interventions are first-line.
• Pharmacological Management (for severe agitation/psychosis): Low-dose antipsychotics (e.g., Haloperidol, Quetiapine) used cautiously and for the shortest duration possible. Avoid benzodiazepines unless alcohol/benzo withdrawal is suspected.

Depression

• Atypical Presentation: Often presents with somatic complaints, anhedonia, and cognitive dysfunction rather than classic sadness.
• Screening Tools: Geriatric Depression Scale (GDS).
• Pharmacological Management:
  • SSRIs (e.g., Escitalopram, Sertraline): First-line due to favorable side effect profile. Watch for hyponatremia, GI upset, sexual dysfunction, increased fall risk.
  • SNRIs (e.g., Venlafaxine, Duloxetine): Also effective, consider for neuropathic pain. Watch for blood pressure elevation, sweating.
  • Other Agents: Bupropion (less sexual dysfunction, activating), Mirtazapine (sedating, appetite stimulant). Avoid TCAs due to anticholinergic burden and cardiac effects.
• Non-pharmacological: Psychotherapy, exercise, social engagement.

Anxiety Disorders

• Presentation: Generalized anxiety disorder (GAD) is common.
• Pharmacological Management:
  • SSRIs/SNRIs: First-line for chronic management.
  • Benzodiazepines (e.g., Lorazepam, Oxazepam): Use with extreme caution, short-term only, lowest effective dose. High risk of sedation, cognitive impairment, falls, and dependence in older adults.

Parkinson's Disease (PD)

• Pathophysiology: Loss of dopaminergic neurons in the substantia nigra.
• Motor Symptoms: Tremor, rigidity, bradykinesia, postural instability (TRAP).
• Non-Motor Symptoms: Depression, anxiety, sleep disturbances, cognitive impairment, psychosis, constipation, orthostatic hypotension.
• Pharmacological Management:
  • Levodopa/Carbidopa: Most effective agent for motor symptoms. Watch for "wearing off," dyskinesias, nausea, orthostatic hypotension.
  • Dopamine Agonists (e.g., Pramipexole, Ropinirole, Rotigotine): Used as monotherapy in early PD or adjunct to levodopa. Higher risk of impulse control disorders, hallucinations, sedation, orthostasis compared to levodopa.
  • MAO-B Inhibitors (e.g., Selegiline, Rasagiline, Safinamide): Mild symptomatic benefit, neuroprotective? Watch for serotonin syndrome with other serotonergic drugs.
  • COMT Inhibitors (e.g., Entacapone, Opicapone): Extend levodopa duration. Watch for dyskinesia exacerbation, diarrhea, urine discoloration.
  • Amantadine: Primarily for dyskinesia. Watch for livedo reticularis, hallucinations.
  • Psychosis in PD: Pimavanserin (selective serotonin inverse agonist), Quetiapine, Clozapine (requires monitoring). Avoid typical antipsychotics and risperidone/olanzapine due to worsening motor symptoms.

Polypharmacy and Drug-Related Problems (DRPs)

• Beers Criteria: Essential for identifying potentially inappropriate medications (PIMs) in older adults.
• STOPP/START Criteria: Complementary tools for identifying PIMs and potential prescribing omissions.
• Anticholinergic Burden: Cumulative effect of medications with anticholinergic properties, leading to cognitive impairment, dry mouth, constipation, urinary retention.
• Fall Risk: Many CNS medications increase fall risk (sedatives, antipsychotics, antidepressants, antihypertensives).

Pharmacokinetics and Pharmacodynamics in Geriatrics

• PK Changes: Decreased hepatic metabolism, decreased renal excretion, altered body composition (increased fat, decreased lean mass, decreased total body water).
• PD Changes: Increased sensitivity to CNS depressants, altered receptor sensitivity.
• Clinical Implications: Start low, go slow; careful dose adjustments; extended dosing intervals.

How It Appears on the Exam: BCGP Question Styles and Scenarios

The BCGP exam will test your ability to apply knowledge to real-world clinical situations. Expect questions that:

• Present a patient case: A geriatric patient with a complex medical history, presenting with new neurological or psychiatric symptoms. You'll need to identify the most likely diagnosis, recommend appropriate pharmacological and non-pharmacological interventions, or identify potential DRPs.
• Focus on drug selection: Given a patient's comorbidities, drug allergies, or current medications, choose the safest and most effective agent for a specific condition (e.g., "Which antidepressant is most appropriate for a patient with severe cardiac disease and glaucoma?").
• Test adverse drug reactions (ADRs): Identify common or serious ADRs associated with specific CNS medications in older adults (e.g., "Which medication is most likely causing the patient's new-onset hyponatremia?").
• Challenge your knowledge of drug interactions: Recognize significant drug-drug or drug-disease interactions (e.g., "What is the primary concern when adding an MAO-B inhibitor to a patient already on an SSRI?").
• Require differentiation of conditions: A scenario describing an older adult with cognitive impairment, and you must distinguish between delirium, dementia, and depression based on symptom characteristics.
• Apply prescribing guidelines: Questions directly or indirectly testing your knowledge of the Beers Criteria, STOPP/START criteria, or other best practice guidelines.
• Evaluate non-pharmacological strategies: Recognize when and how non-drug interventions are appropriate and effective.

To get a feel for the types of questions, be sure to utilize BCGP Board Certified Geriatric Pharmacist practice questions and even some free practice questions available online.

Study Tips: Efficient Approaches for Mastering This Topic

Success on the BCGP exam requires a strategic and focused approach to studying neurological and psychiatric conditions:

1. Master Core Drug Classes: For each condition, know the first-line agents, their mechanisms of action, major adverse effects, and key drug interactions. Create tables or flashcards comparing similar drugs within a class.
2. Understand Pathophysiology: A basic understanding of the underlying disease processes will help you logically deduce treatment strategies and anticipate complications.
3. Focus on Geriatric-Specific Considerations: Always think "geriatric lens." How do PK/PD changes affect dosing? What are the common atypical presentations? Which drugs are particularly problematic in older adults (e.g., anticholinergics, benzodiazepines)?
4. Prioritize Safety: Emphasize identifying and preventing DRPs, applying the Beers Criteria, and recognizing high-risk medications. This is a core competency of geriatric pharmacy.
5. Practice Case Studies: Work through as many patient cases as possible. This is the best way to integrate your knowledge and prepare for the exam's clinical focus. Pay attention to patient demographics, comorbidities, and current medication lists.
6. Differentiate Look-Alike Conditions: Spend time understanding the key differences between delirium, dementia, and depression. Create a comparison chart.
7. Review Guidelines: Familiarize yourself with relevant clinical practice guidelines from organizations like ASHP, ACCP, APhA, and others that publish geriatric-specific recommendations.
8. Utilize Comprehensive Resources: A good study plan should incorporate a variety of resources. For a complete overview, refer to the Complete BCGP Board Certified Geriatric Pharmacist Guide which outlines all critical areas.
9. Active Recall and Spaced Repetition: Don't just passively read. Test yourself frequently, explain concepts in your own words, and revisit difficult topics over time.

Common Mistakes: What to Watch Out For

Even experienced pharmacists can make errors when managing neurological and psychiatric conditions in older adults. Be mindful of these common pitfalls:

• Overlooking Atypical Presentations: Assuming older adults will present with classic symptoms of depression or anxiety can lead to missed diagnoses or inappropriate treatment.
• Failing to Consider Polypharmacy: Not thoroughly reviewing a patient's complete medication list for potential interactions, duplications, or cumulative side effects (e.g., anticholinergic burden).
• Ignoring Non-Pharmacological Interventions: Jumping straight to medication without considering behavioral strategies, environmental modifications, or caregiver education, especially in dementia or delirium.
• Misdiagnosing Cognitive Impairment: Confusing delirium with dementia, or not recognizing depression as a cause of cognitive symptoms (pseudodementia).
• Inappropriate Use of Benzodiazepines: Prescribing benzodiazepines for long-term anxiety or insomnia in older adults due to the high risk of falls, cognitive impairment, and dependence.
• Not Adjusting Doses for Renal/Hepatic Impairment: Failing to modify drug dosages based on age-related physiological changes, leading to accumulation and toxicity.
• Missing Drug-Induced Causes: Attributing new-onset confusion, agitation, or motor symptoms to a new disease process rather than a drug side effect or interaction.
• Underestimating ADRs: Not anticipating the increased sensitivity of older adults to CNS-active medications and their associated adverse effects (e.g., orthostatic hypotension, sedation).
• Lack of Monitoring: Not implementing a robust monitoring plan for efficacy and safety, including symptom scales, lab parameters, and functional status.

Quick Review / Summary

Managing neurological and psychiatric conditions in geriatrics is a cornerstone of advanced pharmacy practice and a critical domain for the BCGP exam. The unique physiological changes, complex comorbidities, and risk of polypharmacy in older adults demand a specialized approach to medication management.

As a BCGP candidate, your ability to differentiate between conditions like delirium, dementia, and depression, select appropriate and safe pharmacological agents, identify and mitigate drug-related problems, and advocate for non-pharmacological interventions will be rigorously tested. By focusing on key concepts, understanding exam question styles, employing effective study strategies, and being aware of common mistakes, you can confidently approach this challenging yet rewarding area of geriatric pharmacy. Your expertise in this field directly translates to improved quality of life and safety for older adult patients.